New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2).

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Bioorganic & Medicinal Chemistry

• Publication date

  2004-05-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.BMC.2004.01.047PMID 15080939
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis

  2009cited by this paper
• Protease inhibitors of the sulfonamide type: Anticancer, antiinflammatory, and antiviral agents

  2003cited by this paper
• Exploring the interface between metallo-proteinase activity and growth factor and cytokine bioavailability.

  2002cited by this paper
• Metalloproteinase inhibitors: biological actions and therapeutic opportunities

  2002cited by this paper
• Design, Synthesis, and Characterization of Potent, Slow-binding Inhibitors That Are Selective for Gelatinases*

  2002cited by this paper
• Gelatinases and their inhibitors in tumor metastasis: from biological research to medical applications.

  2002cited by this paper
• Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor.

  2002cited by this paper
• Structural differences of matrix metalloproteinases with potential implications for inhibitor selectivity examined by the GRID/CPCA approach.

  2002cited by this paper
• Gelatinases A and B.

  2002cited by this paper
• Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations

  2002cited by this paper
• Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.

  2002cited by this paper
• Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chirality.

  2001cited by this paper
• A comparative docking study and the design of potentially selective MMP inhibitors

  2001cited by this paper
• X-ray Absorption Studies of Human Matrix Metalloproteinase-2 (MMP-2) Bound to a Highly Selective Mechanism-based Inhibitor

  2001cited by this paper
• Potent and Selective Mechanism-Based Inhibition of Gelatinases

  2000cited by this paper
• Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related diseases

  2000cited by this paper
• Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.

  2000cited by this paper
• Selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1).

  2000cited by this paper
• Experimental metastasis is suppressed in MMP-9-deficient mice

  1999cited by this paper
• MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover.

  1999cited by this paper
• Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention.

  1999cited by this paper
• In Vitro Models of Angiogenesis: The use of Matrigel

  1999cited by this paper
• Marimastat (BB2516): Current status of development

  1999cited by this paper
• Design and therapeutic application of matrix metalloproteinase inhibitors.

  1999cited by this paper
• Matrix metalloproteinases and metastasis

  1999cited by this paper
• Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor.

  1998cited by this paper
• Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor

  1998cited by this paper
• Reduced angiogenesis and tumor progression in gelatinase A-deficient mice.

  1998cited by this paper
• Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.

  1998cited by this paper
• Membrane-type metalloproteinases in tumor invasion.

  1998cited by this paper
• Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits.

  1997cited by this paper
• Section Review Biologicals & Immunologicals: Matrix metalloproteinases and malignant disease: Recent developments

  1996cited by this paper
• Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis

  1995cited by this paper
• Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments.

  1995cited by this paper
• Remodeling MMPIs

  1995cited by this paper
• Matrix Metalloproteinase-2 Is an Interstitial Collagenase

  1995cited by this paper
• Synthesis and aldose reductase inhibitory activity of N-(arylsulfonyl)- and N-(aroyl)-N-(arylmethyloxy)glycines

  1994cited by this paper
• Reciprocated matrix metalloproteinase activation: a process performed by interstitial collagenase and progelatinase A.

  1994cited by this paper
• A novel coumarin‐labelled peptide for sensitive continuous assays of the matrix metalloproteinases

  1992cited by this paper

• Matrix metalloproteinases proteolyze RAB proteins and contribute to cisplatin-induced ototoxicity

  2026cites this paper
• Fibroblast-Mediated MMP2 Contribution to Nonresponse in Anti-TNFα Therapy for Crohn's Disease.

  2025cites this paper
• Peptide Sequence Modulating the Analytical Performance of Electrogenerated Chemiluminescence Peptide-Based Biosensors for Matrix Metalloproteinase 2.

  2025cites this paper
• Data-Independent Acquisition Proteomics and N-Terminomics Methods Reveal Alterations in Mitochondrial Function and Metabolism in Ischemic-Reperfused Hearts

  2024cites this paper
• High levels of soluble CD73 unveil resistance to BRAF inhibitors in melanoma cells.

  2024cites this paper
• Interleukin-1β activates matrix metalloproteinase-2 to alter lacrimal gland myoepithelial cell structure and function

  2024cites this paper
• N-Terminomic Identification of Intracellular MMP-2 Substrates in Cardiac Tissue

  2024cites this paper
• Two distinct integrin binding sites on MMP9 drive cancer invasion by mediating integrin membrane trafficking & stabilization

  2024cites this paper
• The roles of intracellular proteolysis in cardiac ischemia–reperfusion injury

  2023cites this paper
• Immunomodulatory roles of metalloproteinases in rheumatoid arthritis

  2023cites this paper
• Matrix metalloproteinase-2 proteolyzes mitofusin-2 and impairs mitochondrial function during myocardial ischemia–reperfusion injury

  2023cites this paper
• Isolation, synthesis and medicinal chemistry of biphenyl analogs – A review

  2023cites this paper
• Carborane-Containing Hydroxamate MMP Ligands for the Treatment of Tumors Using Boron Neutron Capture Therapy (BNCT): Efficacy without Tumor Cell Entry

  2023cites this paper
• Identification of N-Acyl Hydrazones as New Non-Zinc-Binding MMP-13 Inhibitors by Structure-Based Virtual Screening Studies and Chemical Optimization

  2023cites this paper
• Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.

  2022cites this paper
• The ACE Inhibitor Lisinopril Stimulates Melanoma Cell Invasiveness by Inducing MMP2 Secretion.

  2022cites this paper
• Staurosporine-induced cleavage of apoptosis-inducing factor in human fibrosarcoma cells is independent of matrix metalloproteinase-2.

  2021cites this paper
• Polymerizable Matrix Metalloproteinases’ Inhibitors with Potential Application for Dental Restorations

  2021cites this paper
• Matrix Metalloproteinase-2 Activated by Ultraviolet-B Degrades Human Ciliary Zonules In Vitro

  2021cites this paper
• Role of transforming growth factor‐β1 in recessive dystrophic epidermolysis bullosa squamous cell carcinoma

  2021cites this paper
• Ligand-based design of anticancer MMP2 inhibitors: a review.

  2021cites this paper
• Carborane‐Containing Matrix Metalloprotease (MMP) Ligands as Candidates for Boron Neutron‐Capture Therapy (BNCT)

  2020cites this paper
• Developments in Carbohydrate-Based Metzincin Inhibitors

  2020cites this paper
• Heroin Seeking and Extinction From Seeking Activate Matrix Metalloproteinases at Synapses on Distinct Subpopulations of Accumbens Cells.

  2020cites this paper
• Collagenases and gelatinases and their inhibitors as anticancer agents

  2020cites this paper
• Cardioprotective Effect of Novel Matrix Metalloproteinase Inhibitors

  2020influential citation
• Junctophilin-2 is a target of matrix metalloproteinase-2 in myocardial ischemia–reperfusion injury

  2019cites this paper
• Myocardial MMP-2 contributes to SERCA2a proteolysis during cardiac ischemia-reperfusion injury.

  2019cites this paper
• Potential of Matrix Metalloproteinase Inhibitors for the Treatment of Local Tissue Damage Induced by a Type P-I Snake Venom Metalloproteinase

  2019cites this paper
• Matrix metalloproteinase inhibitors prevent the release and proteolytic activity of monocyte/macrophage-derived microparticles

  2019cites this paper
• QSAR modelling on a series of arylsulfonamide-based hydroxamates as potent MMP-2 inhibitors

  2019influential citation
• Basal lamina remodeling at the skeletal muscle stem cell niche mediates stem cell self-renewal

  2018cites this paper
• Structural exploration for the refinement of anticancer matrix metalloproteinase-2 inhibitor designing approaches through robust validated multi-QSARs

  2018cites this paper
• Matrix metalloproteinase in the cardiovascular remodeling of hypertension: current insights and therapeutic potential

  2018cites this paper
• Bifunctional Inhibitors as a New Tool To Reduce Cancer Cell Invasion by Impairing MMP-9 Homodimerization.

  2017cites this paper
• Arylsulfonamides and selectivity of matrix metalloproteinase-2: An overview.

  2017cites this paper
• Involvement of PI3K and MMP1 in PDGF-induced Migration of Human Adipose-derived Stem Cells

  2017cites this paper
• Trophoblast survival signaling during human placentation requires HSP70 activation of MMP2-mediated HBEGF shedding

  2017cites this paper
• Current diagnostics and treatment of fibrosarcoma –perspectives for future therapeutic targets and strategies

  2017cites this paper
• Expression and Purification of Matrix Metalloproteinases in Escherichia coli.

  2017cites this paper
• Matrix metalloproteinase-2 in oncostatin M-induced sarcomere degeneration in cardiomyocytes.

  2016cites this paper
• Effects on migration of breast cancer cells in 3D models upon MMP inhibition

  2016cites this paper
• Product Data Sheet Chemical Properties Product

  2016cites this paper
• A local complement response by RPE causes early-stage macular degeneration.

  2015cites this paper
• Dynamic Alterations to α-Actinin Accompanying Sarcomere Disassembly and Reassembly during Cardiomyocyte Mitosis

  2015cites this paper
• Modeling, predicting and virtual screening of selective inhibitors of MMP-3 and MMP-9 over MMP-1 using random forest classification

  2015cites this paper
• Design of Metalloprotease Inhibitors

  2015cites this paper
• Mechanisms of Enhanced Pulmonary Vasoconstriction and Calcium Sensitization Following Chronic Hypoxia

  2015cites this paper
• GnRH-(1-5) activates matrix metallopeptidase-9 to release epidermal growth factor and promote cellular invasion.

  2015cites this paper
• N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.

  2015cites this paper
• Protease Nexin-1 affects the migration and invasion of C6 glioma cells through the regulation of urokinase Plasminogen Activator and Matrix Metalloproteinase-9/2.

  2014cites this paper
• Matrix-Assisted Refolding, Purification and Activity Assessment Using a ‘Form Invariant’ Assay for Matrix Metalloproteinase 2 (MMP2)

  2014cites this paper
• Stress immunity in lymphomas: mesenchymal cells as a target of therapy.

  2014cites this paper
• Inhibition of tumor-associated αvβ3 integrin regulates the angiogenic switch by enhancing expression of IGFBP-4 leading to reduced melanoma growth and angiogenesis in vivo

  2014cites this paper
• DA-Raf–dependent inhibition of the Ras-ERK signaling pathway in type 2 alveolar epithelial cells controls alveolar formation

  2014influential citation
• How to exploit stress-related immunity against Hodgkin’s lymphoma

  2013cites this paper
• Crystallization of bi-functional ligand protein complexes.

  2013influential citation
• Sulphonamides: Deserving class as MMP inhibitors?

  2013cites this paper
• Chymase-mediated intestinal epithelial permeability is regulated by a protease-activating receptor/matrix metalloproteinase-2-dependent mechanism.

  2013cites this paper
• Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: synthesis and biological evaluation.

  2013cites this paper
• Chymase mediated intestinal epithelial permeability is regulated by protease activating 1

  2013cites this paper
• Structure–Activity Relationship Studies of Hydroxamic Acids as Matrix Metalloproteinase Inhibitors

  2013cites this paper
• Inhibitory effects of caspase inhibitors on the activity of matrix metalloproteinase (MMP)‐2

  2012influential citation
• Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: a first round of lead optimization.

  2012cites this paper
• Fibroblasts in omentum activated by tumor cells promote ovarian cancer growth, adhesion and invasiveness.

  2012cites this paper
• New hope for the treatment of osteoarthritis through selective inhibition of MMP-13.

  2011cites this paper
• Recent advances in studies on hydroxamates as matrix metalloproteinase inhibitors: a review.

  2011cites this paper
• Caffeoyl pyrrolidine derivative LY52 inhibits hepatocellular carcinoma invasion via suppressing matrix metalloproteinase-2

  2011cites this paper
• Synthesis of Oximes and Hydroxamic Acids

  2010cites this paper
• Biochemical Characterization of Human Matrix Metalloproteinases and Their Newly Designed Inhibitors Related to Stroke

  2010cites this paper
• Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma.

  2010cites this paper
• Therapeutic potential of sulindac hydroxamic acid against human pancreatic and colonic cancer cells.

  2010cites this paper
• Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.

  2010cites this paper
• Different Subcellular Localization of ALCAM Molecules in Neuroblastoma: Association with Relapse

  2010cites this paper
• Control of melanoma invasiveness by anticollagenolytic agents: a reappraisal of an old concept.

  2009cites this paper
• N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.

  2009cites this paper
• Selective matrix metalloproteinase inhibitors for cancer.

  2009cites this paper
• Proteases as anti-cancer targets--molecular and biological basis for development of inhibitor-like drugs against cancer.

  2009cites this paper
• Role of sulfonamide group in matrix metalloproteinase inhibitors.

  2008cites this paper
• Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.

  2008cites this paper
• Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.

  2007cites this paper
• The ALCAM Shedding by the Metalloprotease ADAM17/TACE Is Involved in Motility of Ovarian Carcinoma Cells

  2007cites this paper
• Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases.

  2006cites this paper
• Using caffeoyl pyrrolidine derivative LY52, a potential inhibitor of matrix metalloproteinase-2, to suppress tumor invasion and metastasis.

  2006cites this paper
• Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides.

  2006cites this paper
• Serotype-selective, small-molecule inhibitors of the zinc endopeptidase of botulinum neurotoxin serotype A.

  2006cites this paper
• Synthesis and screening of N-alkyl hydroxamates for inhibition of cancer cell proliferation.

  2006cites this paper
• A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs.

  2005cites this paper
• N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.

  2005cites this paper